Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04775680
Status:
TERMINATED
Last Update Posted:
2023-04-24
First Post:
2021-02-16
Brief Title:
Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors andor Non Hodgkin Lymphoma
Sponsor:
Adagene Suzhou Limited
Organization:
Adagene Inc
Study Overview
Official Title:
A Multicenter Open-Label Phase IbII Study of ADG106 in Combination With PD-1 Antibody in Advanced Solid Tumors and RelapsedRefractory Non-Hodgkin Lymphoma
Status:
TERMINATED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The safety of ADG106 combined with triprilimab has been fully understoodThe overall clinical benefit of enrolled subjects was limited and further development of ADG106 was reconsidered
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Multicenter Open-Label Phase IbII Study of ADG106 in Combination with PD-1 Antibody in Advanced Solid Tumors and RelapsedRefractory Non-Hodgkin Lymphoma
The primary objective of Phase Ib To evaluate the maximum tolerated dosage MTD of ADG106 in combination with PD-1 antibody in advanced solid tumors and relapsedrefractory non-Hodgkin lymphoma and to determine the recommended phase II clinical studies dosage RP2D
The primary objective of Phase Ib To evaluate the maximum tolerated dosage MTD of ADG106 in combination with PD-1 antibody in advanced solid tumors and relapsedrefractory non-Hodgkin lymphoma and to determine the recommended phase II clinical studies dosage RP2D
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None